CYDY · CytoDyn Inc.
$0.20
0.00 (-0.35%)
At close · Sep 16
Going-concern doubt
— flagged Aug 31, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets and satisfaction of liabilities in the normal course of business. As presented in the accompanying consolidated financial statements, the Company had losses for all periods presented, except for the year ended May 31, 2025 due to a one-time return of clinical expenses. The Company had an accumulated deficit of approximately $930.5 million as of May 31, 2026. These factors, among others, including the various matters discussed in Note 10, Commitments and Contingencies, raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-K filed Aug 31, 2026
Market Cap
$280.53M
Shares
1.38B
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.20
Open$0.20
Day$0.20–0.21
52W close$0.19–0.37
Avg vol 30d1.4M
Short int36.2M · 2.6% float · 15.6d
Short vol37%
DataJan 2020–Sep 2026
Filing10-K · Aug 31
Up next
filed Aug 31, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$42.70M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.8%
Year over year · more shares
Price change (1Y)
-33.3%
Trailing year
Short interest
2.6%
Latest settlement · 15.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 17.7 · elevated
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−24%
below
Price vs 50-day avg
−3%
below
RSI (14)
45
neutral
MACD trend
Negative
52-week position
7%
near low
Momentum
relative strength
1-month return
+2%
trailing
6-month return
−23%
trailing
YTD return
−29%
this year
Relative strength
−38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
-33% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.62% of float · ▼ -0.5% MoM · 15.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
6 holders — near 3-yr low, contrarian setup
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
Free cash flow
$-17.4M
Balance sheet
$26.5M
net debt
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−50%
past year
ATR
8.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−24%
Bearish
Price vs 50-day avg
−3%
Neutral
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
7%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
-33% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.62% of float · ▼ -0.5% MoM · 15.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
6 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 7%
Range high $0
vs 200-day avg -24%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CYDY
this stock
CytoDyn Inc.
|
$280.53M | -28.6% | -100.0% | — | 2.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.06B | +13.2% | +46.2% | 29.9 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.83B | +0.4% | +20.8% | 19.2 | 2.5% |
|
ARGX
Argenx SE
|
$60.93B | +17.1% | — | — | 2.0% |
|
CSLLY
Csl Ltd
|
$59.64B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
6
- % held
- 0.0%
- Net QoQ
- -170.5K sh
- Top holder
- Diversified Trust Co
Held
Float
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CYDY | +2.5% | +1.9% | -23.1% | -15.5% | -28.6% |
| SPY | -1.1% | -1.8% | +14.8% | -1.7% | +10.6% |
| vs SPY | +3.6% | +3.6% | -37.9% | -13.8% | -39.2% |